Showing results (131-140 of 276) with videos related to

Sort By:
Pageof 28
The Lancet. Digital Health|February 24, 2026
End-to-end integrative segmentation and radiomics prognostic models for risk stratification of high-grade serous ovarian cancer: a retrospective multicohort studyKristofer Linton-Reid, Haonan Lu, Georg Wengert, et al.
Journal of Gynecologic Oncology|August 11, 2021
Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trialKeiichi Fujiwara, Hiroyuki Fujiwara, Hiroyuki Yoshida, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|September 17, 2020
LION-PAW (lymphadenectomy in ovarian neoplasm) sexual function assessment: a prospective sub-study of the LION trialAnnette Hasenburg, Jalid Sehouli, Bjoern Lampe, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|May 30, 2020
Association between obesity and vulvar cancer recurrence: an analysis of the AGO-CaRE-1 studyRudiger Klapdor, Peter Hillemanns, Linn Wölber, et al.
The Lancet. Oncology|September 13, 2016
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trialJonathan A Ledermann, Philipp Harter, Charlie Gourley, et al.
Gynecologic Oncology Research and Practice|March 14, 2017
Preference of elderly patients' to oral or intravenous chemotherapy in heavily pre-treated recurrent ovarian cancer: final results of a prospective multicenter trialRadoslav Chekerov, Philipp Harter, Stefan Fuxius, et al.
Human Mutation|September 15, 2018
Diagnosis of Li-Fraumeni Syndrome: Differentiating TP53 germline mutations from clonal hematopoiesis: Results of the observational AGO-TR1 trialKonstantin Weber-Lassalle, Philipp Harter, Jan Hauke, et al.
British Journal of Cancer|December 19, 2021
Validation analysis of the novel imaging-based prognostic radiomic signature in patients undergoing primary surgery for advanced high-grade serous ovarian cancer (HGSOC)Christina Fotopoulou, Andrea Rockall, Haonan Lu, et al.
The Lancet. Oncology|June 3, 2014
Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trialJonathan Ledermann, Philipp Harter, Charlie Gourley, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|November 7, 2023
AGO-OVAR 28/ENGOT-ov57. Niraparib alone versus niraparib in combination with bevacizumab in patients with carboplatin-taxane-based chemotherapy in advanced ovarian cancer: a multicenter randomized phase III trialFlorian Heitz, Christian Marth, Stéphanie Henry, et al.
Pageof 28